RFL - Ordinary Shares - Class B

1.49
0   0%

Share volume: 177,703
Last Updated: 03-09-2026
Real Estate/Real Estate: 0.26%

PREVIOUS CLOSE
CHG
CHG%
$1.49
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
27%
Profitability 0%
Dept financing 30%
Liquidity 75%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
2.76%
1 Month
24.17%
3 Months
-2.61%
6 Months
12.03%
1 Year
-17.22%
2 Year
-11.31%
Key data
Stock price
$1.49
P/E Ratio 
0.00
DAY RANGE
$1.47 - $1.57
EPS 
-$0.86
52 WEEK RANGE
$1.12 - $3.19
52 WEEK CHANGE
-$20.74
MARKET CAP 
69.611 M
YIELD 
1.38%
SHARES OUTSTANDING 
51.763 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
06-13-2025
BETA 
0.39
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$201,274
AVERAGE 30 VOLUME 
$97,120
Company detail
CEO: William Conkling
Region: US
Website: www.rafaelholdings.com
Employees: 20
IPO year: 2018
Issue type: Common Stock
Market: NYSE
Industry: Real Estate/Real Estate
Sector: Finance, Insurance, And Real Estate

Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies and commercial real estate assets. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.

Recent news